A Creative Approach to Third World Markets and to one Start-Up's First Financing
This article was originally published in Start Up
A new three-way agreement between the University of California, Berkeley (UCB), the Gates Foundation, Amyris Biotechnologies Inc., and the Institute for OneWorld Health (IOWH) showcases one approach to creating affordable drugs for third-world markets that aren't attractive to for-profit companies-with incentives for all participants.
You may also be interested in...
An example of the looming power of synthetic biology, one of its first start-ups, Codon Devices, is providing researchers with hundreds of specified protein variants using automated, microarray-based fabrication methods. Its platform could help address pharma's productivity problem by decreasing the size of a discovery pipeline and shrinking the development timeline, and position the company to negotiate downstream payments for its efforts based on the success of clients' development programs.
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?